allodynia from glp-1 Drugs: New Reports of Dysesthesia and Allodynia is being reported with

Matz tailors GLP-1 therapy to each patients unique needs, ensuring that it works effectively as part of a comprehensive weight loss plan

The reduction of visceral fat is regarded as one of the non-glucose-lowering effects of GLP-1RAs, such as liraglutide [54], which may contribute to myocardial protection

Nausea, vomiting, diarrhea, and reduced appetite may make it easier to consume fewer fluids throughout the day

Secondary endpoints Weight loss A difference in weight loss was already seen at M3 (9.2% [3.6] vs

Safety Considerations, Eligibility, and When Tapering May Not Be Advised Tapering is safer for patients whose weight loss goals are achieved or stabilized, metabolic markers improve, and lifestyle habits are established